Responses
Immunology and inflammation
Original research
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
Compose a Response to This Article
Other responses
No responses have been published for this article.